TSLP and IL-33 are key players in both T2 and non-T2 inflammation, and biologics targeting these alarmins, such as tezepelumab, astegolimab, and ecaleralimab, represent promising future therapeutic options for a broader range of severe asthma patients, including those with non-T2 phenotypes. Here, TSLP is linked to asthma.